UVA-1 therapy of localized scleroderma and other diseases accompanied by skin sclerosis

The study results confirm the efficacy of the UVA-1 therapy for patients with localized scleroderma, extragenital lichen sclerosus et atrophicus, sclerodermatous chronic graft-versus-host disease and scleredema adultorum. The therapy has an anti-inflammatory and anti^m^ action, arrests progression and reduces the activity of the disease process, and has a good efficacy and safety profile.

• Publication year

  2013

• Venue

  Vestnik Dermatologii i Venerologii

• Publication date

  2013-10-15

• Fields of study

  Not labeled

• Identifiers
  DOI 10.25208/vdv566
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Persistent polymorphous light eruption after ultraviolet A1 phototherapy

  2013cited by this paper
• Treatment regimens, protocols, dosage, and indications for UVA1 phototherapy: facts and controversies.

  2013cited by this paper
• Effects of arsenite and UVA-1 radiation on calcineurin signaling.

  2012cited by this paper
• Ultraviolet A1 phototherapy: a British Photodermatology Group workshop report

  2012influential reference
• UVA1 irradiation inhibits fibroblast proliferation and alleviates pathological changes of scleroderma in a mouse model

  2012cited by this paper
• UVA1 induces cyclobutane pyrimidine dimers but not 6-4 photoproducts in human skin in vivo.

  2012cited by this paper
• Low‐dose UVA1 phototherapy for scleroderma: what benefit can we expect?

  2012cited by this paper
• Оn the role of pro-fibrous cytokines in the pathogenesis of localized scleroderma

  2012cited by this paper
• Efficiency of UVA1 therapy in complex treatment of chronic dermatosis

  2012cited by this paper
• Effectiveness of medium‐dose ultraviolet A1 phototherapy in localized scleroderma

  2011cited by this paper
• Successful treatment of microstomia with UVA1 phototherapy in systemic sclerosis

  2011cited by this paper
• Cutaneous graft‐versus‐host disease: rationales and treatment options

  2011cited by this paper
• Scleroedema diabeticorum

  2011cited by this paper
• Merkel cell carcinoma arising in immunosuppressed patients treated with high‐dose ultraviolet A1 (320–400 nm) phototherapy: a report of two cases

  2010cited by this paper
• Effects of Ultraviolet A‐1 Radiation on Calcineurin Activity and Cytokine Production in (Skin) Cell Cultures †

  2010cited by this paper
• Scleredema diabeticorum successfully treated with ultraviolet A1 phototherapy

  2010cited by this paper
• Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: a retrospective and prospective study

  2010cited by this paper
• Eosinophilic fascitis: a report of two cases treated with ultraviolet A1 phototherapy

  2009influential reference
• AWMF‐Leitlinie Nr. 013/066 Diagnostik und Therapie der zirkumskripten Sklerodermie

  2009cited by this paper
• Uva1 Phototherapy in the Management of Sclerodermatous Graft-Versus-Host Disease (Gvhd): a report of two cases / Uva1 fototerapija u lečenju sklerodermatoznog oblika hronične Gvhd: Prikaz dva slučaja

  2009cited by this paper
• Medium-dose is more effective than low-dose ultraviolet A1 phototherapy for localized scleroderma as shown by 20-MHz ultrasound assessment.

  2009cited by this paper
• Low‐dose UVA1 phototherapy for proximal and acral scleroderma in systemic sclerosis

  2009cited by this paper
• Diagnosis and Therapy of Localized Scleroderma

  2009cited by this paper
• UV-A1 therapy for nephrogenic systemic fibrosis.

  2009cited by this paper
• Period of remission after treatment with UVA‐1 in sclerodermic skin diseases

  2008cited by this paper
• Efficacy of UVA1 phototherapy in 230 patients with various skin diseases

  2008influential reference
• Ultrastructural changes induced in cutaneous collagen by ultraviolet‐A1 and psoralen plus ultraviolet A therapy in systemic sclerosis

  2008cited by this paper
• Limited effects of UV-A1 phototherapy in 3 patients with nephrogenic systemic fibrosis.

  2008cited by this paper
• Scleredema diabeticorum case series: successful treatment with UV-A1.

  2008cited by this paper
• Effect of increased pigmentation on the antifibrotic response of human skin to UV-A1 phototherapy.

  2008cited by this paper
• UVA1 phototherapy is effective in darker skin: a review of 101 patients of Fitzpatrick skin types I–V

  2008cited by this paper
• Eosinophilic fasciitis and combined UVA1--retinoid--corticosteroid treatment: two case reports.

  2008cited by this paper
• Significant downregulation of transforming growth factor‐β signal transducers in human skin following ultraviolet‐A1 irradiation

  2007cited by this paper
• Differential expression of decorin in localized scleroderma following ultraviolet-A1 irradiation.

  2007cited by this paper
• Ultraviolet A1 phototherapy for treatment of acrosclerosis in systemic sclerosis: controlled study with half‐side comparison analysis

  2007cited by this paper
• Scleredema adultorum associated with type 2 diabetes mellitus: a report of three cases

  2007cited by this paper
• Pigmentation after single and multiple UV-exposures depending on UV-spectrum

  2007cited by this paper
• Ultraviolet A1‐induced downregulation of human β‐defensins and interleukin‐6 and interleukin‐8 correlates with clinical improvement in localized scleroderma

  2006cited by this paper
• UVA1 phototherapy for genital lichen sclerosus

  2006cited by this paper
• A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma.

  2006cited by this paper
• Ultraviolet A1 phototherapy decreases inhibitory SMAD7 gene expression in localized scleroderma

  2006cited by this paper
• Ultraviolet‐A (UVA‐1) radiation suppresses immunoglobulin production of activated B lymphocytes in vitro

  2006cited by this paper
• UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States

  2006influential reference
• Successful UVA1 phototherapy in a patient with scleredema adultorum

  2005cited by this paper
• Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin

  2005cited by this paper
• Ultraviolet-A1 phototherapy modulates Th1/Th2 and Tc1/Tc2 balance in patients with systemic lupus erythematosus.

  2005cited by this paper
• Bivalent effect of UV light on human skin mast cells-low-level mediator release at baseline but potent suppression upon mast cell triggering.

  2005cited by this paper
• An action spectrum for the production of cis-urocanic acid in human skin in vivo.

  2005cited by this paper
• The effect of ultraviolet (UV) A1, UVB and solar‐simulated radiation on p53 activation and p21Waf1/Cip1

  2005cited by this paper
• UV-A1 phototherapy improves nephrogenic fibrosing dermopathy.

  2004cited by this paper
• Immunohistochemical investigations and introduction of new therapeutic strategies in scleromyxoedema: Case report

  2004cited by this paper
• Modulation of endothelial dysfunction and apoptosis: UVA1-mediated skin improvement in systemic sclerosis

  2004cited by this paper
• Different susceptibility of malignant versus nonmalignant human T cells toward ultraviolet A-1 radiation-induced apoptosis.

  2004cited by this paper
• Chronic cutaneous graft-versus-host disease in two children responds to UVA1 therapy: improvement of skin lesions, joint mobility, and quality of life.

  2004cited by this paper
• Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis.

  2004influential reference
• UVA‐1 as a treatment for scleredema

  2004cited by this paper
• UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo

  2004cited by this paper
• Ultraviolet irradiation induces apoptosis in human immature, but not in skin mast cells.

  2003cited by this paper
• The Crucial Role of TGF-β in the Age-Related Alterations Induced by Ultrviolet A Irradiation

  2003cited by this paper
• Altered decorin expression of systemic sclerosis by UVA1 (340–400 nm) phototherapy: Immunohistochemical analysis of 3 cases

  2003cited by this paper
• Alterations in human epidermal Langerhans cells by ultraviolet radiation: quantitative and morphological study

  2003cited by this paper
• Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease.

  2003cited by this paper
• [Pansclerotic porphyria cutanea tarda after chronic exposure to organic solvents].

  2003cited by this paper
• Ultraviolet A1 phototherapy

  2003cited by this paper
• Pansklerotische Skleroporphyrie nach langjähriger Exposition gegenüber organischen Lösungsmitteln

  2003cited by this paper
• The Expression of Matrix Metalloproteinase‐1 mRNA Induced by Ultraviolet A1 (340–400 nm) Is Phototherapy Relevant to the Glutathione (GSH) Content in Skin Fibroblasts of Systemic Sclerosis

  2003cited by this paper
• Evaluation of Medium-Dose UVA1 Phototherapy in Localized Scleroderma with the Cutometer and Fast Fourier Transform Method

  2003cited by this paper
• Influence of UVB, UVA and UVA1 Irradiation on Histamine Release from Human Basophils and Mast Cells In Vitro in the Presence and Absence of Antioxidants ¶

  2003cited by this paper
• Low-dose ultraviolet A1 phototherapy for extragenital lichen sclerosus: results of a preliminary study.

  2002cited by this paper
• p53 mutations as a marker of skin cancer risk: comparison of UVA and UVB effects.

  2002cited by this paper
• UVA1 therapy for sclerodermic graft-versus-host disease of the skin.

  2002cited by this paper
• Opposing effects of UVA1 phototherapy on the expression of bcl-2 and p53 in atopic dermatitis

  2001cited by this paper
• Assoziation zwischen UVA1 bzw. Bade-PUVA-Bestrahlung und Melanomentwicklung?

  2001cited by this paper
• [Association between UVA1 and PUVA bath therapy and development of malignant melanoma].

  2001cited by this paper
• Combined Treatment with Calcipotriol Ointment and Low‐Dose Ultraviolet A1 Phototherapy in Childhood Morphea

  2001cited by this paper
• Improvement of cutaneous manifestations in POEMS syndrome after UVA1 phototherapy.

  2001cited by this paper
• Bullous Pemphigoid in a Patient Treated with UVA-1 Phototherapy for Disseminated Morphea

  2001cited by this paper
• UVA1-Phototherapie bei Lichen sclerosus et atrophicus

  2001cited by this paper
• Ultraviolet AI exposure of human skin results in Langerhans cell depletion and reduction of epidermal antigen‐presenting cell function: partial protection by a broad‐spectrum sunscreen

  2001cited by this paper
• Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells.

  2001cited by this paper
• Effects of low dose ultraviolet A‐1 phototherapy on morphea

  2001cited by this paper
• Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy.

  2000cited by this paper
• Changes in collagen I and collagen III metabolism in patients with generalized atopic eczema undergoing medium‐dose ultraviolet A1 phototherapy

  2000influential reference
• Acrosclerosis in patients with systemic sclerosis responds to low-dose UV-A1 phototherapy.

  2000cited by this paper
• Transforming growth factor‐β1 and ultraviolet A1 radiation increase production of vascular endothelial growth factor but not endothelin‐1 in human dermal fibroblasts

  2000cited by this paper
• Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis.

  2000influential reference
• UV-A1 for keloid.

  1999cited by this paper
• UVA1 radiation triggers two different final apoptotic pathways.

  1999cited by this paper
• Role of UVA in the pathogenesis of melanoma and non‐melanoma skin cancer: A short review

  1999cited by this paper
• UVA therapy for scleroderma.

  1999cited by this paper
• UVA1 for treatment of keloids.

  1999cited by this paper
• [Bleomycin-induced PSS-like pseudoscleroderma. Case report and review of the literature].

  1998cited by this paper
• High-dose UVA1 radiation therapy for localized scleroderma.

  1998influential reference
• Contrasting effects of ultraviolet A1 and ultraviolet B exposure on the induction of tumour necrosis factor‐α in human skin

  1998cited by this paper
• Low-dose UVA phototherapy for treatment of localized scleroderma.

  1998cited by this paper
• Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts.

  1997cited by this paper
• Low dose UVA1 phototherapy in disabling pansclerotic morphoea of childhood

  1997cited by this paper
• Evidence that Singlet Oxygen-induced Human T Helper Cell Apoptosis Is the Basic Mechanism of Ultraviolet-A Radiation Phototherapy

  1997cited by this paper
• Preprogrammed and Programmed Cell Death Mechanisms of Apoptosis: UV‐Induced Immediate and Delayed Apoptosis

  1996cited by this paper
• High-dose ultraviolet A1 (UVA1), but not UVA/UVB therapy, decreases IgE-binding cells in lesional skin of patients with atopic eczema.

  1996influential reference

• No citing papers are available for this paper.